At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
TRC105drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Dose-escalation Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Patients With Stage 4 Non-Squamous Cell Lung Cancer
In Brief
A Phase 1 clinical trial evaluating TRC105 for Non Small Cell Lung Cancer. Completed, enrolled 15 participants.
Detailed Summary
This is a single center, open-label, nonrandomized, phase 1b, dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
Countries--
CollaboratorsUniversity of Alabama at Birmingham
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedDec 2018
Primary CompletionJun 2019
TodayJul 2026
First PostedDec 19, 2018
Enrollment StartSep 1, 2015
Primary CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 7.5 years ago
Interventions
TRC105drug
Dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.